Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech's Lucentis Heads to FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Genentech is touting the breadth and quality of data for the macular degeneration agent, including two Phase III trials and results showing superiority to Novartis/QLT's Visudyne.

You may also be interested in...



Genentech Submits Additional Lucentis Data To FDA

Label for Lucentis, pending for wet age-related macular degeneration, could include data from a Phase IIIb study supporting continuous treatment.

Genentech Submits Additional Lucentis Data To FDA

Label for Lucentis, pending for wet age-related macular degeneration, could include data from a Phase IIIb study supporting continuous treatment.

Lucentis Receives Priority Review

The BLA for Genentech's wet age-related macular degeneration therapy Lucentis (ranibizumab) has been granted six-month priority review by FDA. The user fee date has been set for June 29, 2006

Related Content

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel